Literature DB >> 31414402

ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder.

Ryan Marino1, Jeanmarie Perrone2, Lewis S Nelson3, Timothy J Wiegand4, Evan S Schwarz5, Paul M Wax6, Andrew I Stolbach7.   

Abstract

Entities:  

Keywords:  Buprenorphine; Opioid agonist therapy; Opioid use disorder; Waiver; X-waiver

Mesh：

Substances：

Year:  2019        PMID： 31414402      PMCID： PMC6825058          DOI： 10.1007/s13181-019-00728-9

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN： 1556-9039


× No keyword cloud information.
  19 in total

1.  Barriers and facilitators for emergency department initiation of buprenorphine: A physician survey.

Authors:  Margaret Lowenstein; Austin Kilaru; Jeanmarie Perrone; Jessica Hemmons; Dina Abdel-Rahman; Zachary F Meisel; M Kit Delgado
Journal:  Am J Emerg Med       Date:  2019-02-18       Impact factor: 2.469

Review 2.  Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations.

Authors:  Marion A Coe; Michelle R Lofwall; Sharon L Walsh
Journal:  J Addict Med       Date:  2019 Mar/Apr       Impact factor: 3.702

3.  Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.

Authors:  Bruce R Schackman; Jared A Leff; Daniel Polsky; Brent A Moore; David A Fiellin
Journal:  J Gen Intern Med       Date:  2012-01-04       Impact factor: 5.128

4.  Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.

Authors:  C Holly A Andrilla; Tessa E Moore; Davis G Patterson; Eric H Larson
Journal:  J Rural Health       Date:  2018-06-20       Impact factor: 4.333

Review 5.  The Next Stage of Buprenorphine Care for Opioid Use Disorder.

Authors:  Stephen A Martin; Lisa M Chiodo; Jordon D Bosse; Amanda Wilson
Journal:  Ann Intern Med       Date:  2018-10-23       Impact factor: 25.391

6.  Medical outcomes associated with nonmedical use of methadone and buprenorphine.

Authors:  Samantha Lee; Wendy Klein-Schwartz; Christopher Welsh; Suzanne Doyon
Journal:  J Emerg Med       Date:  2013-05-11       Impact factor: 1.484

Review 7.  A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.

Authors:  Michelle R Lofwall; Sharon L Walsh
Journal:  J Addict Med       Date:  2014 Sep-Oct       Impact factor: 3.702

Review 8.  Improving public health through access to and utilization of medication assisted treatment.

Authors:  Thomas F Kresina; Robert Lubran
Journal:  Int J Environ Res Public Health       Date:  2011-10-24       Impact factor: 3.390

9.  The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales.

Authors:  Dave Marteau; Rebecca McDonald; Kamlesh Patel
Journal:  BMJ Open       Date:  2015-05-29       Impact factor: 2.692

10.  No end to the crisis without an end to the waiver.

Authors:  Joseph W Frank; Sarah E Wakeman; Adam J Gordon
Journal:  Subst Abus       Date:  2018       Impact factor: 3.716
View more
  5 in total

1.  Descriptive Analysis of Inpatient and Outpatient Cohorts Seeking Treatment After Prescription Opioid Misuse and Medical Toxicology Evaluation.

Authors:  Shawn M Varney; Timothy J Wiegand; Paul M Wax; Jeffrey Brent
Journal:  J Med Toxicol       Date:  2021-08-16

2.  Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing.

Authors:  Barbara Andraka-Christou; Adam J Gordon; Joanne Spetz; Rachel Totaram; Matthew Golan; Olivia Randall-Kosich; Jordan Harrison; Spencer Calder; Stefan G Kertesz; Bradley D Stein
Journal:  J Subst Abuse Treat       Date:  2022-01-10

3.  Pharmacists and opioid use disorder care during COVID-19: Call for action.

Authors:  Insaf Mohammad; Dena Berri; Victoria Tutag Lehr
Journal:  J Am Coll Clin Pharm       Date:  2021-11-08

4.  Services Available at United States Addiction Treatment Facilities That Offer Medications versus Behavioral Treatment Only: A Cross-Sectional, Observational Analysis.

Authors:  Andrea Weber; Benjamin Miskle; Alison Lynch; Stephan Arndt; Laura Acion
Journal:  Subst Abuse Rehabil       Date:  2022-09-07

5.  Implementation of a Medication for Addiction Treatment (MAT) and Linkage Program by Leveraging Community Partnerships and Medical Toxicology Expertise.

Authors:  Gillian A Beauchamp; Lexis T Laubach; Samantha B Esposito; Ali Yazdanyar; Paige Roth; Priyanka Lauber; Jamie Allen; Nathan Boateng; Samantha Shaak; David B Burmeister
Journal:  J Med Toxicol       Date:  2020-11-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.